Larvol Delta - Abpro-Announces-Positive-Phase-1-Results-Demonstrating-A-Favorable-Safety-and-Pharmacokinetic-Prole-of-ABP-300-A-Neutralizing-Antibody-Therapeutic-for-the-Treatment-of-COVID19

ABP-300 - Abpro Therap, BIO invest

http://www.globenewswire.com/news-release/2021/02/02/2168138/0/en/Abpro-Announces-Positive-Phase-1-Results-Demonstrating-A-Favorable-Safety-and-Pharmacokinetic-Profile-of-ABP-300-A-Neutralizing-Antibody-Therapeutic-for-the-Treatment-of-COVID-19.html

Feb 2, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next